Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antibiotic replace stronger ones for severe pneumonia?

NCT ID NCT07322549

Knowledge-focused Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This completed study looked at 104 adults in the ICU with severe pneumonia caused by three common bacteria. Researchers checked whether the bacteria were sensitive to amoxicillin/clavulanic acid (AMC) or to third-generation cephalosporins (3GC), which are standard treatments. The goal was to see if AMC could be a good alternative to help reduce antibiotic resistance. The study only reviewed past medical records, so it cannot prove which treatment is better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Amoxicillin/clavulanic acid (AMC) and third-generation cephalosporins (3GC)
What this could lead to
If the results show AMC works well, it could offer a narrower-spectrum antibiotic option for severe pneumonia, potentially reducing antibiotic resistance.
What could go wrong
This is a small, single-center retrospective study, not a controlled trial. It only looks at past data, so it cannot prove which antibiotic is better. Results may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

104 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients admitted to the ICU at Sainte-Musse Hospital between January 2018 and December 2022 with a diagnosis of severe CAP or CAAP

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient admitted to the ICU at Sainte-Musse Hospital between January 2018 and December 2022. 2. Diagnosis of severe CAP or CAAP within 48 hours of hospital admission, documented with Streptococcus pneumoniae, and/or Haemophilus influenzae, and/or Staphylococcus aureus (confirmed by blood culture and/or a respiratory sample), with an available antibiogram. Exclusion Criteria: 1. Patient under 18 years old. 2. Patient hospitalized within 3 months prior to hospital admission. 3. Infectious documentation of another pathogen within 48 hours of hospital admission. 4. Nosocomial pneumonia. 5. Patient under legal guardianship (inmate, legal ward, curatorship).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community-acquired aspiration pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspiration pneumonia Community-Acquired Pneumonia haemophilus infectious disease pneumonia staphylococcal infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe community-acquired pneumonia

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal Toulon La Seyne sur Mer

    Toulon, Var, 83100, France